Floatz logo

Muamycin

HIV Infectious Disease

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

58 Active assets in the HIV Infectious Disease cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
Efavirenz
The Cleveland Clinic
Phase 4BBB
Retrovir
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
NORVIR
Giovanni Di Perri
Phase 4BBB
Nevirapine Anhydrous
Germans Trias i Pujol Hospital
Phase 4BBB

View all 46 →

Same molecule, other indications

Muamycin is also rated in:

colorectal carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
appendix carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
peritoneal carcinomatosisActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →